文献速递冠心病血脂与心血管预防

PDE5抑制剂与前列地尔对冠心病男性生存影响的比较

Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

本研究基于瑞典登记数据,纳入既往心梗或血运重建后接受PDE5抑制剂或前列地尔治疗的男性,比较两组全因死亡等结局。平均随访5.8年,PDE5抑制剂组全因死亡风险低于前列地尔组(HR 0.88,95%CI 0.79-0.98),心肌梗死、心衰、心血管死亡和血运重建风险相似。观察性设计不能推断因果。

要点

  • 稳定冠心病男性中,PDE5抑制剂较前列地尔与更低全因死亡风险相关(HR 0.88,95%CI 0.79-0.98)。
  • PDE5抑制剂与前列地尔相比,心肌梗死、心衰、心血管死亡和血运重建风险相似。
  • 全因死亡下降呈PDE5抑制剂剂量依赖性,但观察性设计不能推断因果。

核心结论

  • 在稳定冠心病男性中,PDE5抑制剂治疗较前列地尔与更低的全因死亡风险相关(HR 0.88,95%CI 0.79-0.98)。
  • PDE5抑制剂与前列地尔在心肌梗死、心衰、心血管死亡和血运重建方面风险相似。
  • 全因死亡下降呈PDE5抑制剂剂量依赖性,但观察性设计不能推断因果或临床获益。

研究设计与样本

  • 基于瑞典患者登记和处方药登记,纳入2006至2013年间事件后超过6个月接受PDE5抑制剂或前列地尔的既往心梗或血运重建男性。
  • 共纳入16,548例PDE5抑制剂治疗男性和1,994例前列地尔治疗男性,平均随访5.8年。
  • 采用Cox回归估计调整后的风险比及95%置信区间。

主要发现

  • PDE5抑制剂组死亡2,261例(14%),前列地尔组死亡521例(26%)。
  • PDE5抑制剂较前列地尔全因死亡风险更低(HR 0.88;95%CI 0.79-0.98)。
  • 以第一五分位为参照,PDE5抑制剂处方第二至第五五分位中第三、第四、第五五分位全因死亡更低。
  • 前列地尔使用者中,第五五分位较第一五分位全因死亡更低。

临床怎么用

  • 对于稳定冠心病合并勃起功能障碍的男性,PDE5抑制剂可能是较前列地尔更优的选择,但需结合个体情况。
  • 不能基于本观察性研究推断PDE5抑制剂的因果获益,临床决策应遵循指南并考虑随机试验证据。

局限性

  • 观察性研究设计不能推断因果关系或临床获益。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Phosphodiesterase 5 inhibitor (PDE5i) treatment is associated with reduced mortality compared with no treatment for erectile dysfunction after myocardial infarction (MI). OBJECTIVES: This study sought to investigate the association between treatment with PDE5i or alprostadil and outcomes in men with stable coronary artery disease. METHODS: All Swedish men with a prior MI or revascularization who received PDE5i or alprostadil during 2006 through 2013 at >6 months after the event were included, using the Swedish Patient Register and the Swedish Prescribed Drug Register. Cox regression was used to estimate adjusted hazard ratios with 95% confidence intervals for all-cause mortality, MI, heart failure, cardiovascular mortality, noncardiovascular mortality, cardiac revascularization, peripheral arterial disease, and stroke in men treated with PDE5i versus alprostadil. RESULTS: This study included 16,548 men treated with PDE5i and 1,994 treated with alprostadil. The mean follow-up was 5.8 years, with 2,261 deaths (14%) in the PDE5i group and 521 (26%) in the alprostadil group. PDE5i compared with alprostadil treatment was associated with lower mortality (hazard ratio: 0.88; 95% confidence interval: 0.79 to 0.98) and with similar associations for MI, heart failure, cardiovascular mortality, and revascularization. When quintiles (q) of filled PDE5i prescriptions were compared using q1 as reference, patients in q3, q4, and q5 had lower all-cause mortality. Among alprostadil users, those in q5 had a lower all-cause mortality compared to q1. CONCLUSIONS: In men with stable coronary artery disease, treatment with PDE5i is associated with lower risks of death, MI, heart failure, and revascularization compared with alprostadil treatment. Although the decrease in all-cause mortality was PDE5i dose dependent, the data do not permit the inference of causality or any clinical benefits of PDE5i because of the observational study design.

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Andersson DP, Landucci L, Lagerros YT, et al. Association of Phosphodiesterase-5 Inhibitors Versus Alprostadil With Survival in Men With Coronary Artery Disease. J Am Coll Cardiol. 2021. PMID: 33766260. doi:10.1016/j.jacc.2021.01.045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。